Literature DB >> 93623

Treatment of myasthenia gravis. Report on 139 patients.

C Scoppetta, P Tonali, A Evoli, P David, F Crucitti, M L Vaccario.   

Abstract

In the treatment of myasthenia gravis (MG) considerable progress has recently been achieved. Our experience is based on the observation of 139 patients with an average follow-up of 3 years and 4 months. A treatment plan and results are presented. Indications for thymectomy: all cases of MG in adult life, apart from ocular myasthenia without radiological thymoma and without electrophysiological and pharmacological signs of generalization; before puberty only cases with radiological thymoma and severely incapacitating or life-threatening signs. Median sternotomy is preferable for thymoma, the transcervical approach with a sternal split for non-neoplastic thymus. Mediastinal radiotherapy is indicated after removal of an invasive or adhesive thymoma. Indications for corticosteroids: 1) before thymectomy: respiratory weakness; 2) soon after thymectomy: life-threatening signs; 3) later after thymectomy: incapacitating or life-threatening signs; 4) as an alternative to thymectomy: when surgery cannot be performed or it is not indicated. Oral Prednisone was nearly always preferred: alternate-day high single dose (75 to 115 mg) has given good results in most cases even if in some cases a small dose was required in the "off day"; inversely a lower alternate-day or daily dose was often sufficient. Long-term results: following this schedule for adult patients good results were scored in 67% of thymomas, in 94% of hyperplasias, and in 62% of unthymectomized patients: in prepuberal life the few cases of severe MG have all shown a favorable evolution.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 93623     DOI: 10.1007/bf00313263

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  42 in total

1.  Studies in myasthenia gravis: early thymectomy. Electrophysiologic and pathologic correlations.

Authors:  G Genkins; A E Papatestas; S H Horowitz; P Kornfield
Journal:  Am J Med       Date:  1975-04       Impact factor: 4.965

2.  THE THYMUS AND OTHER LYMPHOID TISSUES IN CONGENITAL AGAMMAGLOBULINEMIA. II. DELAYED HYPERSENSITIVITY AND HOMOGRAFT SURVIVAL IN A CHILD WITH THYMIC ALYMPHOPLASIA.

Authors:  D GITLIN; F S ROSEN; C A JANEWAY
Journal:  Pediatrics       Date:  1964-05       Impact factor: 7.124

3.  A regional technique for the study of sensitivity to curare in human muscle.

Authors:  J C Brown; J E Charlton; D J White
Journal:  J Neurol Neurosurg Psychiatry       Date:  1975-01       Impact factor: 10.154

Review 4.  Thymectomy in myasthenia gravis: pathologic, clinical, and electrophysiologic correlations.

Authors:  A E Papatestas; G Genkins; S H Horowitz; P Kornfeld
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

5.  Long-term treatment of myasthenia gravis with alternate-day prednisone. Report on 15 patients.

Authors:  P Pinelli; P Tonali; C Scoppetta
Journal:  Eur Neurol       Date:  1974       Impact factor: 1.710

6.  The role of radiotherapy in the management of malignant thymoma.

Authors:  C R Penn; H F Hope-Stone
Journal:  Br J Surg       Date:  1972-07       Impact factor: 6.939

Review 7.  Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients.

Authors:  K E Osserman; G Genkins
Journal:  Mt Sinai J Med       Date:  1971 Nov-Dec

8.  Myasthenia gravis and invasive thymoma: a 20-year experience.

Authors:  A J Goldman; C Herrmann; J C Keesey; D G Mulder; W J Brown
Journal:  Neurology       Date:  1975-11       Impact factor: 9.910

9.  Glucocorticoid-binding components in human thymus hyperplasia.

Authors:  F O Ranelletti; M Carmignani; S Iacobelli; P Tonali
Journal:  Cancer Res       Date:  1978-03       Impact factor: 12.701

10.  Studies in myasthenia gravis: effects of thymectomy. Results on 185 patients with nonthymomatous and thymomatous myasthenia gravis, 1941-1969.

Authors:  A E Papatestas; L I Alpert; K E Osserman; R S Osserman; A E Kark
Journal:  Am J Med       Date:  1971-04       Impact factor: 4.965

View more
  9 in total

1.  Intermittent long-term adrenocorticosteroid treatment of myasthenia gravis.

Authors:  N Wakata; Y Kawamura; M Kobayashi; Y Araki; M Kinoshita
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

2.  Thymectomy for Myasthenia Gravis.

Authors:  Gary S. Gronseth; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.598

Review 3.  Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review.

Authors:  Itay Lotan; Mark A Hellmann; Adi Wilf-Yarkoni; Israel Steiner
Journal:  J Neurol       Date:  2020-10-16       Impact factor: 6.682

4.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12

5.  Myasthenia gravis, thymectomy, and antiacetycholine receptor antibody.

Authors:  E Bartoccioni; F Scuderi; C Scoppetta; A Evoli; P Tonali; L Guidi; C Bartoloni; T Terranova
Journal:  J Neurol       Date:  1980       Impact factor: 4.849

6.  Thymectomy in myasthenia with pure ocular symptoms.

Authors:  F Schumm; H Wiethölter; A Fateh-Moghadam; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-04       Impact factor: 10.154

7.  When is there a full recovery for a myasthenia gravis patient?

Authors:  C Scoppetta; E Bartoccioni; P David; G Flamini; M Lo Monaco; F Scuderi; P Tonali
Journal:  J Neurol       Date:  1982       Impact factor: 4.849

8.  Circulating immune complexes in myasthenia gravis: a study in relation to thymectomy, clinical severity and thymus histology.

Authors:  C Bartoloni; L Guidi; C Scoppetta; P Tonali; E Bartoccioni; G Flamini; G Gambassi; T Terranova
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-10       Impact factor: 10.154

9.  Thymectomy in the treatment of myasthenia gravis: report of 247 patients.

Authors:  A Evoli; A P Batocchi; C Provenzano; E Ricci; P Tonali
Journal:  J Neurol       Date:  1988-05       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.